



DEPARTMENT OF PSYCHIATRY

Office of the Chair - Week of February 27 – March 2, 2012

Website: <http://www.hsc.usf.edu/PSYCH/>

Newsletter

Meetings

- | | | | |
|----------|----------|------------|--|
| Tuesday | 02/28/12 | 12:00 noon | Grand Rounds – “The STEPPS™ (Systems Training for Emotional Predictability and Problem-Solving) Treatment Program for Borderline Personality Disorder”
Jennifer White, M.D., Assistant Professor
Department of Psychiatry
University of South Florida College of Medicine
Nancee Blum, MSW, LISW
Adjunct Clinical Faculty Member, Department of Psychiatry, Adjunct Instructor, University of Iowa Carver College of Medicine |
| Thursday | 03/01/12 | 8:00 a.m. | Call Center Meeting |
| | | | <u>Resident Lectures:</u> |
| | | 8:00 a.m. | PGY-3 – “Long Term Dynamic Therapy”
Dr. Robert Fernandez
CHILD – “Parent Training” Dr. Mariann Suarez |
| | | 9:00 a.m. | PGY-3 – “Clinical Case Conference”
Dr. Kailie Shaw/Beth Reese, LCSW
PGY-4 – “Group Therapy” Dr. John Zak
CHILD – “Parent Training” Dr. Mariann Suarez |
| | | 10:00 a.m. | PGY-3 – “Advanced Psychopharm”
Thea Moore, PharmD
CHILD – “Interpersonal Psychotherapy – Grief”
Dr. Sandra Stock |
| | | 11:00 a.m. | Residents Meeting |
| | | 1:00 p.m. | PGY-1 – “Basic Elements of Psychotherapy”
Dr. Robert Fernandez
GERI – “Pain Management in Life Limiting Illness”
Dr. Jonathan Stewart |

2:00 p.m. PGY-1 – “Introduction to Psychopharm” Dr. Daniel Fallon
PGY-2 – “Introduction to Child – Assessment of Child
And Family. Overview of Prescribing to Kids”
Dr. Sandra Stock

Friday 03/02/12

No Third Year Medical Student Lectures

In The Know!

Happy Birthday Wishes to Dr. Michael Schoenberg/March 4th and Kyle Jennette/March 4th.

Congratulations to Antoinette Bailey for achieving the “Best Oral Presenter” Award at the 2012 USF Health Research Day. She presented “Aberrant T-lymphocyte development and function in mice overexpressing human secreted amyloid precursor protein alpha: implications for autism” which was published in J FASAB, 2012. The authors of the abstract are: Antoinette R. Bailey, Huayan Hou, Demian F. Obregon, Jun Tian, Yuyan Zhu, Qiang Zou, William V. Nikolic, Michael Bengston, Takashi Mori, Tanya Murphy and Jun Tan.

Congratulations to Dr. Demian Obregon. Every year the American College of Psychiatrist selects a small number of psychiatry residents to receive the prestigious Laughlin Fellowship. The fellows are selected from an elite pool of psychiatry residents on the basis of their potential to make a significant impact on the field of psychiatry. This year one of our own residents Dr. Demian Obregon, was selected for the fellowship. Demian’s fellowship included funding to attend and participate in educational lectures, special interest group meetings, and social functions of The College. *Way to go, Demian!*

For information regarding the USF Memory Disorders Clinic, please click on the following link: http://health.usf.edu/medicine/psychiatry/p_memory_disorders_clinic.htm

Research Happenings!

Current Open Studies – Call [813-974-2832](tel:813-974-2832) or [813-974-1404](tel:813-974-1404) for more information on any study or to refer a patient.

Now Open and Enrolling – ADHD Aggression Study

Kids between ages of 6-12 years old and in generally good health with a diagnosis of ADHD are eligible to participate in a 10-week investigational medication trial. They must be receiving stimulant medication treatment for ADHD symptoms for 1 month prior to study enrollment and be experiencing aggressive behaviors. This study is a 10 week investigational medication trial that will test the effectiveness and safety of molindone hydrochloride extended release as an add-on treatment for aggressive behaviors in children with ADHD. Principal Investigator – Mike Bengtson, MD.

[Bipolar I in Teens](#)

This study is a 3- week investigational medication trial that will test the effectiveness and safety of asenapine compared to placebo in teens ages 12-17 with Bipolar I disorder experiencing a manic or mixed episode. A 26-week extension study is available. Study medication, study visits, and required laboratory work provided at no cost. Volunteers must be between the ages of 12-17 years old and in generally good health with a diagnosis of Bipolar I disorder and currently experiencing manic or mixed symptoms. Principal Investigator – Mike Bengtson, MD.

[Now Enrolling - Major Depression - Mixed](#)

A 6-week double-blind study comparing lurasidone to placebo in patients with major depression who are also experiencing some hypomanic symptoms. A 12-week open-label extension study is available. This study is looking at patient who may meet proposed DSM-V criteria for Major Depression – Mixed. PI – Carlos Santana, MD

[Now Enrolling – Bipolar](#)

A 9-month outpatient study of Ramelteon sub-lingual as an adjunctive treatment to prevent relapse of manic/mixed/depressive symptoms in patients 18-75 years who have experienced a manic/mixed/depressed episode within the last 9 months. Patients will continue on current mood stabilizers, antidepressants, or antipsychotic medications throughout the trial. PI – Carlos Santana, MD

[Now Enrolling – Bipolar I Disorder with Depressive Symptoms](#)

An 8-week outpatient study assessing Ramelteon sub-lingual as an adjunctive treatment for patients 18-75 years who are currently experiencing depressive symptoms associated with Bipolar I Disorder. Patients must be on Lithium and/or Depakote. PI – Carlos Santana, MD

[Now Enrolling – Schizophrenia Long-Acting IM Depot Open-label Study](#)

An open-label naturalistic study of Aripiprazole IM (long-acting depot) in patients with schizophrenia 18-65 years. Patients must have been prescribed antipsychotic medication for at least 7 months prior to enrollment and have had at least 1 Inpatient Hospitalization in the past 24 months. PI – Carlos Santana, MD

<http://health.usf.edu/medicine/psychiatry/research/index.htm>

[Quality of Life in Youth with Tic Disorders](#)

A one-time study visit evaluating the quality of life in youth with tic disorders, specifically on various aspects of family functioning and the daily challenges faced by children and their families. Children ages 6-17 years old with a diagnosis of a tic disorder (i.e. Chronic tic disorder or Tourette Syndrome) and are experiencing current tics are eligible to participate. This study is a one-time visit that will include questionnaires and assessments. Participants will also have the opportunity to attend a focus group with youth of similar age assessing kinds of help they received and accessibility of services and the difficulties faced by having tics. Please call (727) 767-8230 for more information. Principal Investigator: Tanya Murphy, MD

Child and Adolescent Tourette's Disorder Guanfacine Clinical Trial

The purpose of this research study is to learn more about the new extended release formula of the drug, guanfacine. This new formula is called *Intuniv*. This study will help us understand how safe and how well this new extended release formula of guanfacine works for children with chronic tics. Your child is being asked to take part in this research study because he/she has been diagnosed with Chronic Motor or Vocal Tic Disorder or Tourette's Disorder. Main symptoms are motor tics such as uncontrolled movements and/or vocal tics such as repeated noises. These tics occur many times a day, nearly every day lasting for at least 1 year. Children ages 6-17 years old are eligible to participate. Please call (727) 767-8230 for more information.

Principal Investigator: Tanya Murphy, MD

Living with Tics: The Living with Tics research study hopes to show how well a type of psychotherapy helps children better cope with tics and become more resilient. Children who are interested to participate must attend an initial assessment to determine eligibility. Eligible participants must be between 8 and 18 years of age, have a diagnosis of Tourette Syndrome or Chronic Tic Disorder, experience tic-related impairment, and either be medication-free or on stable medication. If eligible, interested participants will be randomly assigned to receive immediate psychotherapy or a 10 week waitlist control condition followed by subsequent psychotherapy. As part of the study, there is no charge for the psychotherapy treatment. The immediate psychotherapy condition consists of weekly therapy sessions over a 10 week period. This multi-component treatment approach includes habit reversal training, anger management, problem solving skills and other related therapeutic components to help improve the quality of life for children with chronic tic disorders. Please call (727) 767-8230 for more information. Principal Investigator: Eric Storch PhD.

Adult OCD Ondansetron Clinical Trial

The purpose of this research study is to investigate the effectiveness, safety, and tolerability of 2 dosages Ondansetron as compared to placebo (a substance which looks like an active drug but has no active ingredient) in adult who have OCD and who are currently taking a selective serotonin reuptake inhibitor (SRI) such as Anafranil® (clomipramine) Paxil® (paroxetine), Prozac® (fluoxetine), Luvox® (fluvoxamine, or Zoloft® (sertraline). Another purpose of this study is to find out how the study drug works in the body when taken along with an SSRI.

Please call (727) 767-8230 for more information.

Principal Investigator: Tanya Murphy, MD

Pediatric OCD D-Cycloserine and Cognitive Behavioral Therapy (CBT) Research Study

The purpose of this research study is to examine if d-cycloserine enhances cognitive behavioral therapy for pediatric OCD. Participants will be involved in fifteen clinical visits spanning a nine-month period. Each participant will receive ten sessions of cognitive behavioral therapy and seven doses of the study medication or placebo one hour prior to session. Children ages 7-17 years old are eligible to participate.

Please call (727) 767-8230 for more information.

Principal Investigator: Eric Storch PhD

Cognitive-Behavioral Therapy (CBT) for Anxiety Disorders in Children with Autism Spectrum Disorder Research Study

The purpose of this research study is to examine the efficacy of a manualized cognitive-behavioral therapy to treat anxiety disorders in children with autism spectrum disorders. Therapy sessions last approximately one hour a week for sixteen weeks. In addition, participants will be involved in a number of anxiety and developmental assessments free of charge. Children ages 7-16 years old are eligible to participate. Please call (727) 767-8230 for more information. Principal Investigator: Eric Storch PhD